Experiments on the most important drug in the world

  It treats obesity and reduces deaths from heart disease

A Danish pharmaceutical company is conducting extensive experiments on a new drug aimed at losing weight and reducing obesity, but the results were amazing, as it not only succeeded in combating obesity, but it was also shown that it reduces the risk of death by 18%, which may make it one of the most important drugs in the world.

According to the details published by the British newspaper "Financial Times", the new drug is called (Wegovy), and it is produced by the company "Novo Nordisk" and has already succeeded in losing weight and reducing the risk of death by a significant percentage, according to the results of the sample that was studied.

Health systems and insurance companies

The Danish pharmaceutical company hopes to convince more health systems and insurance companies to pay for this treatment, according to the newspaper.

Martin Holst-Lange, executive vice president of development at Novo Nordisk, said the new data showed in more detail how the drug was “incredibly powerful” in treating cardiovascular risk.

Last August, preliminary data from the trials conducted by the Norwegian company Novo Nordisk on its medicines led to a rise in its share prices in the market by up to 16%, as investors became excited because the results could attract any health systems and insurance companies hesitant to cover the new category of patients. Weight loss medications.

Cost of new medication

The new drug (Wegovy) is considered expensive, as its cost will exceed $1,300 per month.

The Novo Nordisk trial was applied to more than 17,600 people over the age of 45 who suffer from obesity as well as cardiovascular disease, but not diabetes. About 458 patients who took a placebo died during the trial, compared to 375 people who took Wegovy, which represents an 18% reduction in the risk of death.

This information comes after preliminary results showed that patients who took (Wegovy) were 20% more likely to suffer from cardiovascular diseases such as stroke or heart attack compared to participants who received a placebo.

Lang stated that the experiment also showed that the drug has an effect on other conditions such as kidney disease. “I expect to see really interesting data about the effect of the drug on chronic kidney disease,” he commented.